Promising Potential of Silevertinib in EGFR-Mutant NSCLC: Buy Rating Reiterated
I'm PortAI, I can summarize articles.
Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating for Black Diamond Therapeutics, citing promising Phase 2 data for silevertinib in EGFR-mutant NSCLC. The drug showed a 60% response rate and strong CNS efficacy. Burns maintains a $10 price target, supported by a DCF valuation. Piper Sandler also initiated coverage with a Buy rating and a $9 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments